BMT CTN Protocol 1202

Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT.

Below are protocol-related documents, which may be periodically updated.

             Protocol Co-Chair: John Levine, MD (734-936-8456) jelevine@med.umich.edu

             Protocol Co-Chair: John Hansen, MD jhansen@fhcrc.org

             Protocol Officer: Wael Saber, MD wsaber@mcw.edu

             Protocol Coordinator: Dylan Mawby (301-251-1161) bmtctn1202@emmes.com

             Medical Monitor: Wael Saber, MD wsaber@mcw.edu

        

           

The BMT CTN is committed to including widespread transplant community participation in these trials. For information on how to apply to participate on this study, please contact the Protocol Coordinator Dylan Mawby at bmtctn1202@emmes.com for details.